Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

STOCKHOLM, Oct. 6, 2023 /PRNewswire/ — Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and…